About Celimmune
Celimmune is a Healthcare company based in Bethesda (United States) founded in 2015, and was acquired by Amgen in June 2017. IL-15 monoclonal antibodies for celiac disease therapies are developed. The company was acqui-hired. Celimmune offers products and services including Biologic Medicines and Clinical Trials Services. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is Amgen Inc. Its competitors include Biogen, Kymeratx and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Celimmune was founded in 2015 in Bethesda, United States, as a clinical-stage biotechnology firm. Focus is placed on therapies for celiac disease and other immune disorders, utilizing a rapid clinical development approach. The lead candidate, AMG 714an anti-IL-15 monoclonal antibody licensed from Amgenis evaluated in phase-2 trials for non-responsive and refractory celiac disease. Development also includes iVYLISA GIP, a gluten immunoassay for diet management and clinical trial support.
- Headquarters Bethesda, United States
- Stage Acquired
- SectorsHealthcare
- Website celimmune.com
- Social LinkedIn
- Acquired by Amgen (Jun 2017)
- Legal Name Amgen Inc
Products & Services of Celimmune
Celimmune offers a comprehensive portfolio of products and services, including Biologic Medicines and Clinical Trials Services.
Treat serious diseases using innovative biologic technologies
Optimize trials for faster medicine development
Investors in Celimmune
Celimmune has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Amgen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States |
Investor details for Celimmune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Celimmune
2 dated milestones of Celimmune across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Celimmune is founded.
- Exit Acquired by Amgen.
Competitors of Celimmune
Celimmune has 3 listed competitors in our database, 3 of them funded. They include Biogen, Kymeratx and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Celimmune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Celimmune (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Celimmune
Celimmune was founded in 2015.
Celimmune is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.
Celimmune was founded in 2015 in Bethesda, United States, as a clinical-stage biotechnology firm. Focus is placed on therapies for celiac disease and other immune disorders, utilizing a rapid clinical development approach. The lead candidate, AMG 714an anti-IL-15 monoclonal antibody licensed from Amgenis evaluated in phase-2 trials for non-responsive and refractory celiac disease. Development also includes iVYLISA GIP, a gluten immunoassay for diet management and clinical trial support.
Celimmune's top competitors include Kymeratx, PureTech Health and Biogen.
Celimmune offers Biologic Medicines and Clinical Trials Services.
Celimmune has 1 investor. Key investors include Amgen.
Celimmune operates through Amgen Inc.
Yes. Celimmune was acquired by Amgen in June 2017.